Actively Recruiting
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Led by BeiGene · Updated on 2026-04-17
146
Participants Needed
29
Research Sites
351 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy expansion cohorts
CONDITIONS
Official Title
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed and dated informed consent before study participation
- ECOG Performance Status between 0 and 2
- Adequate coagulation, liver, kidney, and pancreatic function
- For Phase 1: Confirmed diagnosis of relapsed or refractory Marginal Zone Lymphoma, Follicular Lymphoma (grade 1-3a), Waldenstr�f6m Macroglobulinemia, non-GCB DLBCL, Richter's transformation to DLBCL, Mantle Cell Lymphoma, or CLL/SLL
- For Phase 2: Confirmed diagnosis of Mantle Cell Lymphoma or CLL/SLL
- Use of highly effective birth control during treatment and for at least 90 days after last dose
You will not qualify if you...
- Prior malignancy within 2 years except certain treated skin, bladder, cervical, breast, or low-risk prostate cancers
- Need for ongoing systemic treatment for other cancers or systemic corticosteroids
- Treatment with strong CYP3A inhibitors or inducers within 14 days before first dose, or proton-pump inhibitors within 5 days
- Current or past central nervous system involvement
- Recent autologous stem cell transplant less than 3 months ago, chimeric cell therapy less than 6 months ago, or allogeneic stem cell transplant less than 6 months ago
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 29 locations
1
The First Affiliated Hospital of Bengbu Medical University
Bengbu, Anhui, China, 233004
Actively Recruiting
2
Anhui Provincial Hospital
Hefei, Anhui, China, 230000
Actively Recruiting
3
Peking University Third Hospital
Beijing, Beijing Municipality, China, 100000
Actively Recruiting
4
Beijing Chao Yang Hospital,Capital Medical University
Beijing, Beijing Municipality, China, 100020
Actively Recruiting
5
Second Affiliated Hospital of Army Medical University (Xinqiao Hospital)
Chongqing, Chongqing Municipality, China, 400037
Actively Recruiting
6
Fujian Medical University Union Hospital
Fuzhou, Fujian, China, 350001
Actively Recruiting
7
Sun Yat Sen University Cancer Center
Guangzhou, Guangdong, China, 510060
Actively Recruiting
8
Guangdong Provincial Peoples Hospital Huifu Branch
Guangzhou, Guangdong, China, 510120
Actively Recruiting
9
The Peoples Hospital of Guangxi Zhuang Autonomous Region
Nanning, Guangxi, China, 530021
Actively Recruiting
10
Nanyang Central Hospital
Nanyang, Henan, China, 473000
Actively Recruiting
11
Henan Cancer Hospital
Zhengzhou, Henan, China, 450000
Actively Recruiting
12
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430022
Actively Recruiting
13
Xiangyang Central Hospital
Xiangyang, Hubei, China, 441021
Actively Recruiting
14
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China, 410011
Actively Recruiting
15
Jiangsu Province Hospital
Nanjing, Jiangsu, China, 210029
Actively Recruiting
16
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China, 215006
Actively Recruiting
17
The First Affiliated Hospital of Nanchang University Branch Donghu
Nanchang, Jiangxi, China, 330006
Actively Recruiting
18
Jiangxi Province Cancer Hospital
Nanchang, Jiangxi, China, 330029
Actively Recruiting
19
The First Hospital of Jilin University
Changchun, Jilin, China, 130021
Actively Recruiting
20
Affiliated Zhongshan Hospital of Dalian University
Dalian, Liaoning, China, 116001
Actively Recruiting
21
Shandong Cancer Hospital
Jinan, Shandong, China, 250117
Actively Recruiting
22
Qingdao Central Hospital
Qingdao, Shandong, China, 266031
Actively Recruiting
23
Rui Jin Hospital Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China, 200025
Actively Recruiting
24
Shanxi Provincial Cancer Hospital
Taiyuan, Shanxi, China, 030013
Actively Recruiting
25
West China Hospital, Sichuan University
Chengdu, Sichuan, China, 610041
Actively Recruiting
26
Institute of Hematology and Hospital of Blood Disease
Tianjin, Tianjin Municipality, China, 300020
Actively Recruiting
27
First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China, 650032
Actively Recruiting
28
The First Affiliated Hospital, Zhejiang University School of Medicine Branch Yuhang
Hangzhou, Zhejiang, China, 311121
Actively Recruiting
29
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China, 325000
Actively Recruiting
Research Team
B
BeiGene
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here